Evidence map›Paper›PMID 41084890›Full record

ArticleJournal of comparative effectiveness research2025

Healthcare cost comparison between first-line ibrutinib and acalabrutinib in chronic lymphocytic leukemia patients in the Veterans Affairs.

Lindsey Fitzgerald, Sabyasachi Ghosh, Alex Bokun, Angela Lax, Fan Mu, Eric Wu, Yilu Lin, Lizheng Shi, Zaina P Qureshi, Solomon A Graf

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of comparative effectiveness research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lindsey FitzgeraldDivision of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.ORCID 0000-0001-5988-2878
Sabyasachi GhoshJanssen Scientific Affairs, a Johnson & Johnson Company, Horsham, PA 19044, USA.
Alex BokunJanssen Scientific Affairs, a Johnson & Johnson Company, Horsham, PA 19044, USA.ORCID 0000-0002-2622-6513
Angela LaxAnalysis Group, Inc., Boston, MA 02199, USA.ORCID 0000-0001-9577-8904
Fan MuAnalysis Group, Inc., Boston, MA 02199, USA.
Eric WuAnalysis Group, Inc., Boston, MA 02199, USA.
Yilu LinDepartment of Health Policy & Management, School of Public Health & Tropical Medicine, Tulane University, New Orleans, LA 70112, USA.ORCID 0000-0001-7040-4287
Lizheng ShiDepartment of Health Policy & Management, School of Public Health & Tropical Medicine, Tulane University, New Orleans, LA 70112, USA.ORCID 0000-0002-7827-6766
Zaina P QureshiJanssen Scientific Affairs, a Johnson & Johnson Company, Horsham, PA 19044, USA.ORCID 0000-0001-9605-3980
Solomon A GrafDivision of Hematology/Oncology, University of Washington School of Medicine, Seattle, WA 98195, USA.ORCID 0000-0002-9475-3016

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdenineBenzamidesHealth Care CostsLeukemia, Lymphocytic, Chronic, B-CellPiperidinesProtein Kinase InhibitorsPyrazinesAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesUnited StatesUnited States Department of Veterans AffairsacalabrutinibAdenineBenzamidesibrutinibPiperidinesProtein Kinase InhibitorsPyrazinesacalabrutinibBTKiCLLcostsHRUibrutinibreal-worldveterans

Identifiers

PMID41084890
PMCPMC12580920

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.